<DOC>
	<DOCNO>NCT00347503</DOCNO>
	<brief_summary>Evaluation aqueous concentration 2 topical NSAIDS well PGE2 inhibition human patient .</brief_summary>
	<brief_title>Aqueous Concentrations PGE2 Inhibition Ketorolac 0.4 % vs. Bromfenac 0.09 % Cataract Patients</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Bromfenac</mesh_term>
	<criteria>Healthy Male/Female 21 year age old . Patient understands willing sign write informed consent form Likely complete entire course study . Patient schedule undergo cataract surgery Female patient childbearing potential must regular menstrual cycle prior study entry ( female consider childbearing potential unless postmenopausal , without uterus and/or ovary , bilateral tubal ligation ) . Patient willing able administer eye drop record time drop instilled Patient use topical NSAID within 1 week study entry Patient know sensitivity ingredient study medication Patient sight one eye Patient history previous intraocular surgery Patient â€™ doctor determine condition ( i.e. , UNCONTROLLED systemic disease ) situation may put significant risk , confound study result may interfere significantly participation study Female patient pregnant , nursing infant planning pregnancy Patients currently involve another investigational study participate one within 30 day prior enter study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>